Vanguard Group
OCEA

Vanguard Group’s Ocean Biomedical, Inc. Common Stock OCEA Stock Holding History

Vanguard Group’s Portfolio OCEA Stock Details OCEA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-406,529
Closed -$22K – 4347
2025
Q1 		$22K Hold
406,529
– – ﹤0.01% 4240
2024
Q4 		$225K Hold
406,529
– – ﹤0.01% 4081
2024
Q3 		$398K Hold
406,529
– – ﹤0.01% 4028
2024
Q2 		$496K Buy
406,529
+135,877
+50% +$232K ﹤0.01% 4008
2024
Q1 		$1.02M Buy
270,652
+118,655
+78% +$223K ﹤0.01% 3802
2023
Q4 		$100K Buy
151,997
+11,360
+8% +$15.6K ﹤0.01% 4298
2023
Q3 		$548K Buy
140,637
+99,014
+238% +$455K ﹤0.01% 4026
2023
Q2 		$250K Buy
+41,623
New +$244K ﹤0.01% 4273

Other funds holding OCEA

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Vanguard Group's OCEA Position: Q2 2025 in Review

Vanguard Group sold out of Ocean Biomedical, Inc. Common Stock (OCEA) in Q2 2025, closing a stake of 406,529 shares — an estimated $22K sold.

Vanguard Group first reported a position in OCEA in Q2 2023 and held it in 8 quarters. The position peaked at $1.02M in Q1 2024. 7 funds tracked by Wall St. Rank hold OCEA as of Q2 2025.

  • Vanguard Group reported no remaining Ocean Biomedical, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 406,529 Ocean Biomedical, Inc. Common Stock shares in Q2 2025, an estimated $22K.
  • Vanguard Group first reported a position in Ocean Biomedical, Inc. Common Stock in Q2 2023 and held it in 8 quarters.
  • Vanguard Group's Ocean Biomedical, Inc. Common Stock position peaked at $1.02M in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Ocean Biomedical, Inc. Common Stock as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.